Why Is Unichem Laboratories Share Price Falling: Key Reasons and Investor Analysis 2026
- May 8, 2026
- Posted by: Harsh Piplani
- Category: News
The Unichem Laboratories share price falling by 40 percent from its 52 week high of Rs 648 to the current level of Rs 392 has attracted significant investor attention. This article explains the key reasons behind the Unichem Laboratories share price falling trend, provides a full financial analysis, and outlines whether this represents a buying opportunity or a value trap heading into 2026. Track Unichem Laboratories live on the Univest Screener.
Click Here to Get Premium Research on Univest
Unichem Laboratories Stock Price Snapshot
| Parameter | Value |
|---|---|
| NSE Ticker | UNICHEMLAB |
| Sector | Pharma |
| CMP April 2026 | Rs 392 |
| 52 Week High | Rs 648 |
| 52 Week Low | Rs 352 |
| Decline from 52W High | 40 percent |
Top Reasons Why Unichem Laboratories Share Price Is Falling
Raw material price surge squeezing EBITDA margins
Raw material price surge squeezing EBITDA margins is the primary driver behind the Unichem Laboratories share price falling trend observed over the past several months. Investors tracking Unichem Laboratories on the Univest Screener would have noticed the correlation between this factor and the stock’s decline from Rs 648 to Rs 392.
Capex cycle delay pushing profitability recovery
Capex cycle delay pushing profitability recovery has compounded the pressure on the Unichem Laboratories share price, extending the fall beyond what many investors initially expected when the stock first began its correction from the 52 week high of Rs 648. For live FII or DII data, check the Univest Screener.
Broad Market Correction Weighing on Pharma Stocks
The April 2026 US 26 percent reciprocal tariff announcement triggered a broad sell-off across Indian equity markets, with the Pharma sector particularly affected. This macro overhang has contributed significantly to Unichem Laboratories share price falling from elevated valuation levels reached at the 52 week high of Rs 648.
Valuation De-Rating After Peak Multiples
Unichem Laboratories had reached premium valuation multiples at Rs 648 that were difficult to sustain without consistent earnings beats. When growth expectations moderated, the de-rating process accelerated the Unichem Laboratories share price falling to Rs 392. Download the Univest iOS App to track valuation metrics in real time.
FII Selling and Institutional Rebalancing
Foreign institutional investors have been net sellers in several mid and small cap segments of the Indian market since the US tariff shock of April 2026. This institutional selling has amplified the Unichem Laboratories share price falling trend beyond what company-specific fundamentals alone would justify.
Financial Analysis: What the Numbers Show
| Metric | Current | At 52W High | Commentary |
|---|---|---|---|
| Share Price | Rs 392 | Rs 648 | Down 40 percent |
| 52 Week Low | Rs 352 | Above | Current price above 52W low |
| Revenue (Rs Cr) | Refer NSE filing | Refer NSE filing | Refer NSE/BSE filing |
| Net Profit PAT (Rs Cr) | Refer NSE filing | Refer NSE filing | Refer NSE/BSE filing |
If you want to track Unichem Laboratories’s live financial metrics and peer comparison, check the Univest Screener for real-time data.
Technical Signals for Unichem Laboratories Share Price
Unichem Laboratories is trading at Rs 392, below its 50 day, 100 day, and 200 day simple moving averages. The stock has formed a pattern of lower highs and lower lows since its 52 week high of Rs 648, confirming a downtrend on charts. Key support is at Rs 352. Key resistance is at Rs 648 where overhead supply will create selling pressure on any recovery attempt. Track Unichem Laboratories technical signals on the Univest Android App.
Can Unichem Laboratories Share Price Recover?
Despite the current headwinds, genuine recovery catalysts exist for long-term investors. First, if the Pharma sector sees a positive re-rating as macro conditions improve, Unichem Laboratories as an established player is likely to benefit. Second, any quarterly earnings result that beats the now reduced expectations could trigger a sharp short-covering rally. Third, a reversal in FII sentiment toward Indian equities would lift Unichem Laboratories alongside the broader market.
The contrarian view is that at Rs 392, with the stock down 40 percent from its peak, some of the bad news is already priced in. Valuation has compressed to a more reasonable level. For the latest research on Unichem Laboratories, subscribe to Univest Pro for premium stock analysis.
Conclusion
The Unichem Laboratories share price falling by 40 percent from Rs 648 to Rs 392 reflects a combination of broad market headwinds, sector-specific pressures, FII selling, earnings deceleration and valuation de-rating. Investors should monitor upcoming quarterly results, changes in FII ownership, and management commentary on the growth recovery trajectory. For real-time tracking and research, use the Univest Screener.
This article is for informational and educational purposes only and is not investment advice. Univest is SEBI registered (INH000013776). Please consult a SEBI registered financial advisor before making any investment decision.
Frequently Asked Questions
Why is Unichem Laboratories share price falling in 2026?
Unichem Laboratories share price falling in 2026 is due to raw material price surge squeezing ebitda margins, combined with broader market pressure from the US tariff shock of April 2026 and FII selling. The stock has declined 40 percent from its 52 week high of Rs 648 to the current Rs 392.
What is the 52 week high and low of Unichem Laboratories?
The 52 week high of Unichem Laboratories is Rs 648 and the 52 week low is Rs 352. The current price of Rs 392 represents a decline of 40 percent from the 52 week high.
Should I buy Unichem Laboratories shares at Rs 392?
Whether to buy Unichem Laboratories at Rs 392 depends on your investment horizon and risk appetite. The stock has fallen 40 percent from its peak, which improves the risk-reward for patient investors with a 2 to 3 year view. However, near-term volatility may persist. Always consult a SEBI registered financial advisor before investing.
What is the latest news affecting Unichem Laboratories stock?
Recent developments affecting Unichem Laboratories include the US 26 percent reciprocal tariff announcement triggering FII selling, Q3 FY26 earnings results showing deceleration, and sector-level analyst estimate revisions in the Pharma space. Track the latest news on the Univest Screener.
What are the recovery triggers for Unichem Laboratories?
Key recovery triggers for Unichem Laboratories include a quarterly earnings beat versus reduced expectations, reversal of FII selling as global macro conditions improve, sector re-rating driven by positive policy developments, and the broader Indian market recovering from the US tariff-related correction.
What are the key downside risks to Unichem Laboratories’s stock?
Key risks to any Unichem Laboratories recovery thesis include continued earnings estimate downgrades, further FII selling if global risk appetite stays negative, unexpected regulatory changes in the Pharma sector, and a deeper than expected correction in the broader Indian equity market.
Recent Article
Why Is Liberty Shoes Share Price Falling: Key Reasons and Investor Analysis 2026
Why Is Shemaroo Entertainment Share Price Falling: Key Reasons and Investor Analysis 2026
Why Is Orchid Pharma Share Price Falling: Key Reasons and Investor Analysis 2026
Why Is Bajaj Holdings and Investment Share Price Falling: Key Reasons and Investor Analysis 2026
Why Is Prism Johnson Share Price Falling: Key Reasons and Investor Analysis 2026
